
UK plan to require drug makers to pay higher rebates draws criticism from industry group
A U.K. government proposal to raise mandatory rebates that drug companies are required to pay to bolster the National Health Service has sparked criticism from
A U.K. government proposal to raise mandatory rebates that drug companies are required to pay to bolster the National Health Service has sparked criticism from
In an instant, more than 1,000 patients at my health care clinic outside Nairobi lost access to lifesaving HIV treatments. Thousands more could no longer
Artificial intelligence can transform medicine in a myriad of ways, including its promise to act as a trusted diagnostic aide to busy clinicians.
Results from the NRG Oncology GOG-0263 phase III clinical trial testing the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for
Mehmet Oz has committed to defending Medicare drug price negotiations in court if he is confirmed to lead CMS. The nominee sailed through a roughly
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
The once-fledgling field of MASH drug developers is now one of the few areas of consistency in the biotech industry. And another late-stage startup is
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Greg Behar’s shakeup of Recipharm is paying off in his first year as CEO. The CDMO reported record-high revenues on Friday, and the company expects
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS